Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 10/20 | 0.72 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.72 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | STK39 | Q9UEW8 | 2/20 | 0.58 |
| ▸ | RORC | P51449 | 1/20 | 0.56 |
| ▸ | PNLIP | P16233 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | SMO | Q99835 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15171235 | 0.91 | TLR8 (0.76) | TLR8TLR7RXFP1ALDH1A1HTT | |
| SCHEMBL15171164 | 0.89 | RORC (0.66) | TLR8TLR7RXFP1ALDH1A1HTT | |
| SCHEMBL15164887 | 0.85 | TLR8 (0.65) | TLR8TLR7RXFP1ALDH1A1HTT | |
| SCHEMBL15164907 | 0.85 | PNLIP (0.60) | TLR8TLR7RXFP1ALDH1A1HTT | |
| SCHEMBL3455896 | 0.82 | RXFP1 (0.88) | RXFP1ALDH1A1HTTMEN1LMNA | |
| SCHEMBL15164892 | 0.82 | MAPK1 (0.76) | ALDH1A1HTTTDP1STK39PNLIP | |
| SCHEMBL14384680 | 0.81 | MTNR1A (0.66) | TLR8TLR7HTTMEN1LMNA | |
| SCHEMBL5369677 | 0.81 | RORC (0.76) | RXFP1TDP1RORCMEN1MAPT | |
| SCHEMBL15164875 | 0.80 | PNLIP (0.76) | ALDH1A1HTTTDP1STK39PNLIP | |
| SCHEMBL15171233 | 0.80 | TLR8 (0.85) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563759-B1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC (US) | 2022-04-06 | — | — | EP | disclosed |
| US-9353099-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150361075-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-12-17 | — | — | US | disclosed |
| US-9090612-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140243366-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8754219-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130203818-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243366-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | TLR8 4453/4885TLR7 4757/4885RXFP1 2109/4885 |
| US-20130203818-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | TLR8 4453/4885TLR7 4757/4885RXFP1 2109/4885 |
| US-20150361075-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | TLR8 4453/4885TLR7 4757/4885RXFP1 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.